Artificial Intelligence in the Pharmaceutical Industry: A Literature Review

ABSTRACT

Artificial Intelligence (AI) is rapidly transforming the pharmaceutical industry through its integration into pharmacovigilance, drug discovery, predictive analytics, and healthcare governance systems. Traditional pharmacovigilance frameworks rely heavily on spontaneous reporting systems and manual signal detection processes, resulting in delayed identification of adverse drug reactions, fragmented healthcare datasets, and under-reporting. AI-driven technologies such as Machine Learning (ML), Natural Language Processing (NLP), and predictive analytics provide scalable solutions capable of improving adverse drug reaction detection, automated signal identification, and clinical decision-making efficiency. This review critically evaluates the role of AI in pharmaceutical systems with specific emphasis on pharmacovigilance, drug discovery, sustainability, ESG integration, ethical governance, and regulatory preparedness. The study also analyses challenges associated with AI implementation, including algorithmic bias, lack of transparency, data privacy risks, and uneven applicability in emerging healthcare systems such as India. The findings demonstrate that AI has the potential to shift pharmaceutical systems from reactive compliance-based frameworks toward predictive and data-driven healthcare infrastructures. However, sustainable implementation requires strong governance mechanisms, explainable AI models, ethical accountability, and continuous human oversight.

KEYWORDS

• Algorithmic Bias
• CIOMS
• Clinical Decision Support
• Data Privacy
• Digital Health
• Drug
• Discovery
• Electronic Health Records

Showing references and in-text citations exactly as published.

• DOI10.5530/jppcm.20260122Copy

RELATED ARTICLES

Matched on section and article type within this issue of JPPCM.

• Review · VOLUME 12, ISSUE 4Exploring Pathogenesis, Clinical Manifestations, and Management of Human Metapneumovirus InfectionGaurao Damre, Snehal Sathe, Dhanashree Shinde, Vaibhav V Bhone · pp. 196-201Review ArticleSame type: Review
• Review · VOLUME 12, ISSUE 4Role of Amyloid Beta and Tau Protein in Alzheimer’s diseaseRajkumari Lodhi, Virendra Kumar Sharma · pp. 202-210Review ArticleSame type: Review
• Review · VOLUME 12, ISSUE 44D Printed Stimuli-Responsive Polypills for Personalized Drug Therapy: Advances, Challenges, and Future PerspectivesAbdul Manaf Fathima Zanooja · pp. 211-216Review ArticleSame type: Review
• Review · VOLUME 12, ISSUE 4Disquisition of Drug Dose Determinations to Effectuate Sustained Therapeutic Response in Patients: A Comprehensive ReviewPooja Chandrasekar, Mariyam Susan Joji, Sashtipriyaa Ramesh, Jagadeesan Moorthy · pp. 217-227Review ArticleSame type: Review